In several myeloid and lymphoid malignancies, driver mutations leading to constitutive JAK activation are available. The paradigm is represented by BCR-ABL1 Autonomous activation in the JAK/STAT pathway is central in numerous pathologies. Genetic alterations targeting this signaling pathway are related largely with hematologic malignancies. Pathological JAK activation also occurs in https://heinzs888kbo5.rimmablog.com/profile